Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES H SCHULTZ

Allopathic & Osteopathic Physicians Family Medicine

NPI
1356376164
CMS profile
658220
Location
ESCONDIDO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$59.18

3 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

Nature of paymentAmountRecords
Food and Beverage $59.18 3

By paying entity

PY2019 · entire year · sorted by reported total

Paying entityAmountRecords
Novo Nordisk Inc $22.15 1
AbbVie, Inc. $19.24 1
Amarin Pharma Inc. $17.79 1

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES H SCHULTZ

NPI 1356376164 · CMS profile ID 658220

Allopathic & Osteopathic Physicians / Family Medicine

ESCONDIDO, CA

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1356376164?year=2019&recipient=provider#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES H SCHULTZ, NPI 1356376164, CMS profile ID 658220. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1356376164?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JAMES H SCHULTZ, NPI 1356376164, CMS profile ID 658220. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1356376164?year=2019&recipient=provider#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JAMES H SCHULTZ, NPI 1356376164, CMS profile ID 658220, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 1 of 1; records 1–3 of 3 matching records. This page contains 3 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1356376164?year=2019&recipient=provider#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

3 matching records · $59.18 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 3 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 1–3 of 3.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Amarin Pharma Inc. $17.7910/02/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 699228385 CMS
Novo Nordisk Inc $22.1506/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 674445369 CMS
AbbVie, Inc. $19.2405/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 647741273 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $59.18 3
PY2020 $63.02 3
PY2021 $1,574.29 2
PY2022 $55.88 3
PY2023 $3,863.08 7
PY2024 $2,152.07 33
PY2025 $1,055.00 4

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $659,253.73 104
PY2024 Recipient $48,637.04 5
PY2024 Principal investigator $695,064.02 430
PY2023 Recipient $11,583.04 6
PY2023 Principal investigator $285,021.08 179
PY2022 Recipient $96,487.00 3
PY2022 Principal investigator $144,410.00 2
PY2020 Principal investigator $92,548.80 14
PY2019 Principal investigator $639,103.36 87

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

87 records in PY2019

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 CIPLA USA INC. $137.10 12/26/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714405
Principal investigator 1 CIPLA USA INC. $23,175.00 12/26/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714415
Principal investigator 1 Hikma Pharmaceuticals USA $8,000.00 12/20/2019 Non-covered Recipient Entity
Aviva Research
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641060901
Principal investigator 1 CIPLA USA INC. $1,700.00 12/19/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714375
Principal investigator 1 CIPLA USA INC. $1,700.00 12/19/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714413
Principal investigator 1 CIPLA USA INC. $1,700.00 12/19/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714419
Principal investigator 1 CIPLA USA INC. $1,700.00 12/19/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714739
Principal investigator 1 CIPLA USA INC. $334.44 12/12/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714409
Principal investigator 1 CIPLA USA INC. $824.34 12/12/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714745
Principal investigator 1 CIPLA USA INC. $1,000.00 12/05/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714741
Principal investigator 1 CIPLA USA INC. $707.04 12/05/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694714747
Principal investigator 1 CIPLA USA INC. $6,000.00 11/05/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694713377
Principal investigator 1 CIPLA USA INC. $15,111.00 11/05/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694713381
Principal investigator 1 SANOFI-AVENTIS U.S. LLC $1,947.00 10/28/2019 Non-covered Recipient Entity
Aviva Research
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers No dispute reported 06/30/2026 691589392
Principal investigator 1 CIPLA USA INC. $9.00 10/23/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694716247
Principal investigator 1 CIPLA USA INC. $10.00 10/23/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694716251
Principal investigator 1 CIPLA USA INC. $10.00 10/11/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694716999
Principal investigator 1 CIPLA USA INC. $10.00 10/11/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694717003
Principal investigator 1 SANOFI-AVENTIS U.S. LLC $2,351.00 10/07/2019 Non-covered Recipient Entity
Aviva Research
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers No dispute reported 06/30/2026 691589193
Principal investigator 1 SANOFI-AVENTIS U.S. LLC $1,947.00 10/07/2019 Non-covered Recipient Entity
Aviva Research
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers No dispute reported 06/30/2026 691589199
Principal investigator 1 CIPLA USA INC. $20.25 10/03/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694716417
Principal investigator 1 CIPLA USA INC. $27.60 10/03/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694716431
Principal investigator 1 CIPLA USA INC. $34.50 10/03/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694716435
Principal investigator 1 CIPLA USA INC. $24.00 10/01/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715435
Principal investigator 1 CIPLA USA INC. $36.00 10/01/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715437
Principal investigator 1 CIPLA USA INC. $18.35 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694710275
Principal investigator 1 CIPLA USA INC. $27.00 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694710347
Principal investigator 1 CIPLA USA INC. $18.40 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694711877
Principal investigator 1 CIPLA USA INC. $100.00 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694711879
Principal investigator 1 CIPLA USA INC. $25.00 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694711883
Principal investigator 1 CIPLA USA INC. $16.80 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694712041
Principal investigator 1 CIPLA USA INC. $1.24 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694712099
Principal investigator 1 CIPLA USA INC. $62.00 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694713605
Principal investigator 1 CIPLA USA INC. $20.00 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694713609
Principal investigator 1 CIPLA USA INC. $85.60 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715393
Principal investigator 1 CIPLA USA INC. $1,519.92 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715395
Principal investigator 1 CIPLA USA INC. $28.00 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715399
Principal investigator 1 CIPLA USA INC. $152.40 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715401
Principal investigator 1 CIPLA USA INC. $69.00 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694715405
Principal investigator 1 CIPLA USA INC. $2.70 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694717159
Principal investigator 1 CIPLA USA INC. $52.31 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694717825
Principal investigator 1 CIPLA USA INC. $9.10 09/17/2019 Non-covered Recipient Entity
AVIVA RESEARCH
U-FS-MU-AS3120 No dispute reported 06/30/2026 694717829
Principal investigator 1 SANOFI-AVENTIS U.S. LLC $1,250.00 08/19/2019 Non-covered Recipient Entity
Aviva Research
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers No dispute reported 06/30/2026 691588987
Principal investigator 1 SANOFI-AVENTIS U.S. LLC $30.00 08/19/2019 Non-covered Recipient Entity
Aviva Research
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers No dispute reported 06/30/2026 691588995
Principal investigator 1 SANOFI-AVENTIS U.S. LLC $100.00 08/19/2019 Non-covered Recipient Entity
Aviva Research
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers No dispute reported 06/30/2026 691589011
Principal investigator 1 SANOFI-AVENTIS U.S. LLC $4,000.00 08/05/2019 Non-covered Recipient Entity
Aviva Research
A 26-week Randomized, Open-label, Active-controlled, 2-treatment Arm, Parallel Group Multi-center Study, Comparing the Efficacy and Safety of Soliqua 100/33 Versus Lantus in Ethnically/Racially Divers No dispute reported 06/30/2026 691588641
Principal investigator 1 Hikma Pharmaceuticals USA $126,824.58 08/01/2019 Non-covered Recipient Entity
Aviva Research
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641060751
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 06/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629173591
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 06/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629174019
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $100.00 06/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629174231
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $158.00 06/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629175047
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $100.00 06/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629175633
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 06/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629175829
Principal investigator 1 GlaxoSmithKline, LLC. $11,135.91 06/18/2019 Non-covered Recipient Entity
AVIVA RESEARCH
A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GRO No dispute reported 06/30/2026 669957437
Principal investigator 1 Hikma Pharmaceuticals USA $182,914.30 06/17/2019 Non-covered Recipient Entity
Aviva Research
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641060775
Principal investigator 1 GlaxoSmithKline, LLC. $875.52 06/04/2019 Non-covered Recipient Entity
AVIVA RESEARCH
A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GRO No dispute reported 06/30/2026 669959587
Principal investigator 1 AstraZeneca Pharmaceuticals LP $3,106.80 05/23/2019 Non-covered Recipient Entity
Aviva Research
Efficacy and Safety of Glycopyrronium/Formoterol Fumarate Fixed-dose Combination Relative to Umeclidinium/Vilanterol Fixed-dose Combination Over 24 Weeks in Patients With Moderate to Very Severe Chronic Obstructive Pulmonary Disease No dispute reported 06/30/2026 684974862
Principal investigator 1 GlaxoSmithKline, LLC. $4,693.52 04/15/2019 Non-covered Recipient Entity
AVIVA RESEARCH
A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GRO No dispute reported 06/30/2026 669972167
Principal investigator 1 Hikma Pharmaceuticals USA $105,883.72 04/03/2019 Non-covered Recipient Entity
Aviva Research
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641060755
Principal investigator 1 Hikma Pharmaceuticals USA $2,618.16 04/03/2019 Non-covered Recipient Entity
Aviva Research
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641060761
Principal investigator 1 Hikma Pharmaceuticals USA $29,939.26 04/03/2019 Non-covered Recipient Entity
Aviva Research
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641060768
Principal investigator 1 CHIESI USA, INC. $2,700.00 04/01/2019 Non-covered Recipient Entity
AVIVA RESEARCH
CCD-05993AA3-01 No dispute reported 06/30/2026 700958593
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $20.00 03/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629174439
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 03/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629174847
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $50.00 03/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629175245
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $858.00 03/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629176209
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $34.19 03/21/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629176769
Principal investigator 1 Hikma Pharmaceuticals USA $9,000.00 03/15/2019 Non-covered Recipient Entity
Aviva Research
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641060661
Principal investigator 1 Hikma Pharmaceuticals USA $1,200.00 03/15/2019 Non-covered Recipient Entity
Aviva Research
Fluticasone Salmeterol Powder, 100mcg50mcg Multicenter Clinical Endpoint Study No dispute reported 06/30/2026 641060668
Principal investigator 1 GlaxoSmithKline, LLC. $4,075.00 03/06/2019 Non-covered Recipient Entity
AVIVA RESEARCH
A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GRO No dispute reported 06/30/2026 669958969
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,680.00 02/11/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629173373
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,051.00 02/11/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629174647
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,680.00 02/11/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629176397
Principal investigator 1 SANOFI-AVENTIS U.S. LLC $6,000.00 02/11/2019 Non-covered Recipient Entity
Aviva Research
A 26-week randomized, open-label, active-controlled, 2-treatment arm, parallel group multi-center study, comparing the efficacy and safety of Soliqua 100/33 versus Lantus in ethnically/racially divers No dispute reported 06/30/2026 691567601
Principal investigator 1 SANOFI-AVENTIS U.S. LLC $1,167.00 02/11/2019 Non-covered Recipient Entity
Aviva Research
A 26-week randomized, open-label, active-controlled, 2-treatment arm, parallel group multi-center study, comparing the efficacy and safety of Soliqua 100/33 versus Lantus in ethnically/racially divers No dispute reported 06/30/2026 691567615
Principal investigator 1 CHIESI USA, INC. $15.00 02/02/2019 Non-covered Recipient Entity
AVIVA RESEARCH
CCD-05993AA3-02 No dispute reported 06/30/2026 700959635
Principal investigator 1 CHIESI USA, INC. $800.00 01/31/2019 Non-covered Recipient Entity
AVIVA RESEARCH
CCD-05993AA3-02 No dispute reported 06/30/2026 700959637
Principal investigator 1 SANOFI-AVENTIS U.S. LLC $21,224.00 01/28/2019 Non-covered Recipient Entity
Aviva Research
A 26-week randomized, open-label, active-controlled, 2-treatment arm, parallel group multi-center study, comparing the efficacy and safety of Soliqua 100/33 versus Lantus in ethnically/racially divers No dispute reported 06/30/2026 691567053
Principal investigator 1 AstraZeneca Pharmaceuticals LP $17,992.47 01/24/2019 Non-covered Recipient Entity
Aviva Research
Study to Assess the Efficacy and Safety of PT010 Relative to PT003 and PT009 in Subjects With Moderate to Very Severe COPD (Ethos) No dispute reported 06/30/2026 684974867
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $1,512.00 01/18/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629173153
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $656.00 01/18/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629173807
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $2,409.00 01/18/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629175439
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $775.00 01/18/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629176021
Principal investigator 1 Bayer HealthCare Pharmaceuticals Inc. $904.00 01/18/2019 Non-covered Recipient Entity
Aviva Research
Bay1002670 Fibroids Efficacy US / CN No dispute reported 06/30/2026 629176583
Principal investigator 1 CHIESI USA, INC. $66.00 01/18/2019 Non-covered Recipient Entity
AVIVA RESEARCH
CCD-05993AA3-01 No dispute reported 06/30/2026 700958591
Principal investigator 1 GlaxoSmithKline, LLC. $15,381.84 01/08/2019 Non-covered Recipient Entity
AVIVA RESEARCH
A PHASE III, RANDOMIZED, DOUBLE-BLIND, ACTIVE CONTROLLED, PARALLEL GRO No dispute reported 06/30/2026 669955025
Principal investigator 1 CHIESI USA, INC. $3,200.00 01/05/2019 Non-covered Recipient Entity
AVIVA RESEARCH
CCD-05993AA3-02 No dispute reported 06/30/2026 700959633